This article is more than 5 years old. Information may no longer be current.

iCo Therapeutics to begin phase 2 trial for novel DME drug

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

VANCOUVER, British Columbia - iCo Therapeutics Inc. will launch a phase 2 clinical trial for iCo-007, an antisense drug targeting c-Raf kinase, according to a company press release.

The phase 2, randomized iDEAL study will examine the tolerability and bioactivity of intravitreal injection of iCo-007 alone or in combination therapy for the treatment of diabetic macular edema. The trial will be conducted at multiple sites across the United States.

"We are very pleased to see yet another significant iCo-007 development milestone occurring in a timely fashion," Andrew Rae, president and CEO of iCo, said in the release. "We expect to be able to provide further commentary on clinical and regulatory developments in the United States, as well as ongoing partnering prospects, in the near future."

A phase 1 trial for iCo-007 was successfully completed in 2010, according to the release.